Dihexa
Dihexa is a small, metabolically stabilised angiotensin IV analogue studied in the laboratory for effects on synapse formation and memory, with proposed relevance to neurodegenerative disease. Its evidence base is entirely preclinical, it has no completed human clinical trials, and it is not an approved therapeutic.
Mechanism
In plain terms, dihexa is being studied for its ability to encourage the formation of new connections between brain cells. Technically, it is a modified angiotensin IV-derived peptide reported to potentiate hepatocyte growth factor (HGF) signalling through its receptor c-Met, thereby promoting synaptogenesis (the formation of dendritic spines and synapses) in preclinical models. Because the work is preclinical, its mechanism and effects in humans are not established.
Regulatory Status by Region
- United States (FDA)Not FDA-approved; an experimental nootropic peptide with no approved therapeutic use.
- Australia (TGA)Not on the ARTG; an unapproved experimental substance.
- European Union (EMA)No EMA marketing authorisation; not an approved medicine in the EU.
- WADANot named on the Prohibited List, but as a non-approved substance it is captured by S0 (Non-Approved Substances), prohibited at all times; athletes should treat it as prohibited.